Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

NCT02251717 PHASE2 COMPLETED Results posted

This study will evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) for 12 or 24 weeks in adults with chronic genotype 1 or genotype 4 hepatitis C virus (HCV) infection who have had a kidney transplant.

Details

Lead sponsor	Gilead Sciences
Phase	PHASE2
Status	COMPLETED
Enrolment	114
Start date	Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jun 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatitis C Virus Infection

Interventions

• LDV/SOF

Countries

Austria, France, Germany, Italy